PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gesamtlänge aller Episoden: 2 days 12 hours 26 minutes
IL-6 Receptor Inhibition in RA: New Perspectives in Optimal Patient Care
IL-6 Receptor Inhibition in RA: New Perspectives in Optimal Patient Care
Updates in the Management of Psoriasis and Psoriatic Arthritis in Canada: Considerations for Clinical Practice
Visit https://www.peervoice.com/MCD860 to view the entire programme with slides.
Teaming Up to Improve Outcomes in Immunology: The Importance of an Integrated Approach to Disease Control
Visit https://www.peervoice.com/SUW860 to view the entire programme with slides.
Elimination of Hepatitis C: Simple Changes for Comprehensive Results
Elimination of Hepatitis C: Simple Changes for Comprehensive Results
Targeting Remission in Auto-Inflammatory Diseases With Anti─IL-1β
Targeting Remission in Auto-Inflammatory Diseases With Anti─IL-1β
Imagining a World Without Hepatitis C Virus: A Call to Action
Imagining a World Without Hepatitis C Virus: A Call to Action
On the Path to Least Resistance in HIV: Long-Term Strategies to Mitigate the Risk of Antiretroviral Resistance
Visit https://www.peervoice.com/MNE860 to view the entire programme with slides.
Adapting to Evolving Paradigms in Atopic Dermatitis: Canadian Consensus Recommendations
Visit https://www.peervoice.com/ZCQ860 to view the entire programme with slides.
Less is More: A Journal Club on the Impact of Reducing Glucocorticoid Use in Patients With Severe Asthma
Visit https://www.peervoice.com/PDE860 to view the entire programme with slides.
Learning From the Literature: The Latest Evidence on JAK Inhibitors for RA
Learning From the Literature: The Latest Evidence on JAK Inhibitors for RA